A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07023627 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: INCB123667

Sponsor

Incyte Corporation

Collaborators

[object Object]
[object Object]